Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs

    Access Status
    Open access via publisher
    Authors
    Norata, Giuseppe
    Ballantyne, C.
    Catapano, A.
    Date
    2013
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Norata, G. and Ballantyne, C. and Catapano, A. 2013. New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs. European Heart Journal. 34 (24).
    Source Title
    European Heart Journal
    DOI
    10.1093/eurheartj/eht088
    ISSN
    0195-668X
    School
    School of Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/55365
    Collection
    • Curtin Research Publications
    Abstract

    Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel agents. Among them are modulators of apoB containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative targets such as lipoprotein(a) also require attention; however, until we have a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the most sound clinical approach. © 2013 Author(s).

    Related items

    Showing items related by title, author, creator and subject.

    • Strategies for the use of nonstatin therapies
      Pirillo, A.; Norata, Giuseppe; Catapano, A. (2017)
      Purpose of review: Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in particular, high levels of low-density lipoprotein cholesterol (LDL-C) have been associated to a higher cardiovascular risk. ...
    • Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: The atherosclerosis risk in communities study
      Lopez, F.; Agarwal, S.; MacLehose, R.; Soliman, E.; Sharrett, A.; Huxley, Rachel; Konety, S.; Ballantyne, C.; Alonso, A. (2012)
      Background-Several cardiovascular risk factors have been associated with the risk of atrial fibrillation (AF). Limited and inconsistent evidence exists on the association of blood lipid levels and lipid-lowering medication ...
    • IDOL N342S variant, atherosclerosis progression and cardiovascular disorders in the italian general population
      Dhyani, A.; Tibolla, G.; Baragetti, A.; Garlaschelli, K.; Pellegatta, F.; Grigore, L.; Norata, Giuseppe; Catapano, A. (2015)
      Inducible degrader of the low density lipoprotein receptor (IDOL), is an E3 ubiquitin ligase that negatively modulates low density lipoprotein receptor (LDL-R) expression. Genome-wide association studies (GWAS) indicated ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.